Royalty Pharma (RPRX) RBC Capital Markets Global Healthcare Conference 2025 summary

Business overview and evolution

• One of the largest global funders of life sciences, specializing in royalty-based funding for over 25 years.

• Evolved from academic royalty monetization to buying and creating royalties, including synthetic royalties as a funding mechanism.

• Public since 2020, with $3B+ in annual revenue and a capital deployment target of $2–2.5B per year.

• Owns royalties on 40–45 products, with a compounding growth model and a large buyback program announced in 2024.

Investment approach and diligence

• Focuses on building a portfolio of impactful products, prioritizing patient and system value over pure financial return.

• Employs a deep diligence process, leveraging a 30-person research and investments team and a robust data science group.

• Passive investment style requires extensive upfront diligence, including proprietary market evaluations and real-world evidence analysis.

• IP diligence is a core competency, with significant investment in legal expertise and a willingness to walk away if IP risks are too high.

Market trends and funding environment

• Sees ongoing capital needs in biopharma, with synthetic royalties filling a gap between equity and debt funding.

• Business is not countercyclical but benefits from both strong and weak funding environments.

• R&D funding deals allow companies to fund single drugs or programs, with recent activity including a $250M deal with Biogen for a lupus drug.